Clinical Trial Update: Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Anti-Tac(Fv)-PE38 (LMB-2) for chronic lymphocytic leukemia completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Anti-Tac(Fv)-PE38 (LMB-2) (Anti-Tac(Fv)-PE38)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphocytic | Phase 2 | Status: COMPLETED | Results posted: 2012-11-15